{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T02:06:42Z","timestamp":1702606002693},"reference-count":51,"publisher":"Microbiology Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:p>Despite the development of new vaccine formulations using new biotechnology resources to combat emerging and re-emerging diseases, serogroup B meningococcal disease is still a worldwide burden, accounting for many deaths and disabilities every year. The successful approach of coupling a polysaccharide (PS) with a carrier protein in order to increase long-lasting immunity could not be exploited against<jats:italic>Neisseria meningitidis<\/jats:italic>B because of the limitations of using the capsular PS of serogroup B meningococci. Tailor-made vaccines based on exposed proteins were shown to be a promising approach to overcome these flaws. However, the continuous adaptation of surface meningococcal structures to the external environment has led to genetic shifts of potential vaccine-target epitopes, hampering the quest for a broad-range vaccine that could be used against all serogroups, especially against serogroup B.<\/jats:p>","DOI":"10.1099\/jmm.0.011189-0","type":"journal-article","created":{"date-parts":[[2009,8,12]],"date-time":"2009-08-12T14:38:32Z","timestamp":1250087912000},"page":"1127-1132","source":"Crossref","is-referenced-by-count":5,"title":["Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins"],"prefix":"10.1099","volume":"58","author":[{"given":"Ivano","family":"de Filippis","sequence":"first","affiliation":[{"name":"Fundacao Oswaldo Cruz, Instituto Nacional de Controle de Qualidade em Sa\u00fade, Departamento de Microbiologia, Rio de Janeiro 21045-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/CVI.00097-06","article-title":"Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate","volume":"13","author":"Beernink","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1086\/514821","article-title":"Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine","volume":"195","author":"Beernink","year":"2007","journal-title":"J Infect Dis"},{"key":"R3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/14789450.4.5.667","article-title":"Postgenomics of Neisseria meningitidis for vaccines development","volume":"4","author":"Bernardini","year":"2007","journal-title":"Expert Rev Proteomics"},{"key":"R4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3201\/eid0402.980210","article-title":"Haemophilus influenzae invasive disease in the United States, 1994\u20131995: near disappearance of a vaccine-preventable childhood disease","volume":"4","author":"Bisgard","year":"1998","journal-title":"Emerg Infect Dis"},{"key":"R5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001432-200206000-00006","article-title":"Current concepts in the role of the host response in Neisseria meningitidis septic shock","volume":"15","author":"Brandtzaeg","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"R6","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/IAI.72.7.4217-4223.2004","article-title":"NadA diversity and carriage in Neisseria meningitidis","volume":"72","author":"Comanducci","year":"2004","journal-title":"Infect Immun"},{"key":"R7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.diagmicrobio.2004.10.004","article-title":"Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene","volume":"51","author":"de Filippis","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1128\/JCM.43.2.838-842.2005","article-title":"Sequence variation in the porB gene from B\u200a:\u200aP1.4 meningococci causing New Zealand's epidemic","volume":"43","author":"Dyet","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/oxfordjournals.molbev.a026061","article-title":"The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis","volume":"16","author":"Feil","year":"1999","journal-title":"Mol Biol Evol"},{"key":"R10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14712598.5.2.273","article-title":"Recent developments in Neisseria meningitidis group A conjugate vaccines","volume":"5","author":"Frasch","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMcp063561","article-title":"Clinical practice. Prevention of meningococcal disease","volume":"355","author":"Gardner","year":"2006","journal-title":"N Engl J Med"},{"key":"R12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/IAI.73.2.1151-1160.2005","article-title":"The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies","volume":"73","author":"Giuliani","year":"2005","journal-title":"Infect Immun"},{"key":"R13","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.4049\/jimmunol.160.10.5028","article-title":"Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid","volume":"160","author":"Granoff","year":"1998","journal-title":"J Immunol"},{"key":"R15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.vaccine.2006.08.001","article-title":"Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults","volume":"25","author":"Halperin","year":"2007","journal-title":"Vaccine"},{"key":"R16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.inf.0000160954.90881.29","article-title":"Outbreak of invasive Haemophilus influenzae serotype a disease","volume":"24","author":"Hammitt","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R17","doi-asserted-by":"crossref","first-page":"e2159","DOI":"10.1371\/journal.pone.0002159","article-title":"A phase II, randomized study on an investigational DTPw-HBV\/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana","volume":"3","author":"Hodgson","year":"2008","journal-title":"PLoS One"},{"key":"R18","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/IAI.71.12.6844-6849.2003","article-title":"Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies","volume":"71","author":"Hou","year":"2003","journal-title":"Infect Immun"},{"key":"R19","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2005.11.006","article-title":"Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens","volume":"24","author":"Jacobsson","year":"2006","journal-title":"Vaccine"},{"key":"R20","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","author":"J\u00f3dar","year":"2003","journal-title":"Lancet"},{"key":"R21","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.vaccine.2006.03.092","article-title":"Improved immunogenicity of a H44\/76 group B outer membrane vesicle vaccine with over-expressed genome-derived neisserial antigen 1870","volume":"25","author":"Koeberling","year":"2007","journal-title":"Vaccine"},{"key":"R22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"R23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1365-2958.1996.981457.x","article-title":"A global gene pool in the neisseriae","volume":"21","author":"Maiden","year":"1996","journal-title":"Mol Microbiol"},{"key":"R24","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0264-410X(00)00047-5","article-title":"Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine","volume":"18","author":"Martin","year":"2000","journal-title":"Vaccine"},{"key":"R25","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.293.12.1433","article-title":"New vaccine should ease meningitis fears","volume":"293","author":"Mitka","year":"2005","journal-title":"JAMA"},{"key":"R26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/08830180109043034","article-title":"Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide","volume":"20","author":"Moe","year":"2001","journal-title":"Int Rev Immunol"},{"key":"R27","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1128\/IAI.70.11.6021-6031.2002","article-title":"Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains","volume":"70","author":"Moe","year":"2002","journal-title":"Infect Immun"},{"key":"R28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2958.1997.5211882.x","article-title":"Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread","volume":"25","author":"Morelli","year":"1997","journal-title":"Mol Microbiol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0264-410X(01)00410-8","article-title":"Vaccine prevention of meningococcal disease, coming soon?","volume":"20","author":"Morley","year":"2001","journal-title":"Vaccine"},{"key":"R30","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1016\/j.vaccine.2005.02.021","article-title":"Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis","volume":"23","author":"Norheim","year":"2005","journal-title":"Vaccine"},{"key":"R31","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1128\/IAI.72.11.6511-6518.2004","article-title":"Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential","volume":"72","author":"O'Dwyer","year":"2004","journal-title":"Infect Immun"},{"key":"R32","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1128\/IAI.70.7.3621-3626.2002","article-title":"Neisseria lactamica protects against experimental meningococcal infection","volume":"70","author":"Oliver","year":"2002","journal-title":"Infect Immun"},{"key":"R33","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"R34","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/14712598.5.12.1611","article-title":"Towards an improved serogroup B Neisseria meningitidis vaccine","volume":"5","author":"Perrett","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"R35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"R36","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Medical progress: meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"R37","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0264-410X(99)00402-8","article-title":"Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys","volume":"18","author":"Rouppe van der Voort","year":"2000","journal-title":"Vaccine"},{"key":"R38","article-title":"The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic","author":"Sexton","year":"2004a"},{"issue":"1","key":"R39","article-title":"Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand","volume":"117","author":"Sexton","year":"2004b","journal-title":"N Z Med J"},{"key":"R40","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"R41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/14760584.3.5.533","article-title":"Control and lot release of meningococcal group C conjugate vaccines","volume":"3","author":"Suker","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"R42","first-page":"U1016","article-title":"Prevention of group B meningococcal disease by vaccination: a difficult task","volume":"117","author":"Thomas","year":"2004","journal-title":"N Z Med J"},{"key":"R43","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","article-title":"Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component","volume":"149","author":"Thompson","year":"2003","journal-title":"Microbiology"},{"key":"R44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-3083.2005.01671.x","article-title":"The immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide","volume":"62","author":"Tiwana","year":"2005","journal-title":"Scand J Immunol"},{"key":"R45","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1086\/518283","article-title":"Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000\u20132006: invasive disease due to non-type B strains","volume":"44","author":"Tsang","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R46","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1128\/IAI.70.5.2454-2462.2002","article-title":"Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells","volume":"70","author":"Unkmeir","year":"2002","journal-title":"Infect Immun"},{"key":"R47","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","author":"Urwin","year":"2004","journal-title":"Infect Immun"},{"key":"R48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/14760584.2.5.673","article-title":"Meningococcal serogroup B infections: a search for a broadly protective vaccine","volume":"2","author":"Vermont","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"R49","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/CVI.00039-07","article-title":"Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines","volume":"14","author":"Wedege","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R50","volume-title":"Control of Epidemic Meningococcal Disease , WHO practical guidelines","year":"1998"},{"key":"R51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.011189-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T09:24:29Z","timestamp":1685093069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.011189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.011189-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]}}}